Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Vitrakvi (larotrectinib)
i
Other names:
LOXO-101, ARRY 470, ARRY-470, LOXO 101, LOXO101, ARRY470, BAY2757556
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(184)
News
Twitter
Trials
Company:
Bayer, Pfizer
Drug class:
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
Related drugs:
‹
entrectinib (172)
AB-106 (5)
GW441756 (1)
KRC-108 (1)
entrectinib (172)
AB-106 (5)
GW441756 (1)
KRC-108 (1)
›
Associations
(184)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
NTRK3 fusion
Non Small Cell Lung Cancer
NTRK3 fusion
Non Small Cell Lung Cancer
larotrectinib
Sensitive: A2 - Guideline
ELCC 2023 - 1 week (New C3)
larotrectinib
Sensitive
:
A2
ELCC 2023 - 1wk
larotrectinib
Sensitive: A2 - Guideline
ELCC 2023 - 1 week
larotrectinib
Sensitive
:
A2
ELCC 2023 - 1 week - (New C3)
NTRK2 fusion
Non Small Cell Lung Cancer
NTRK2 fusion
Non Small Cell Lung Cancer
larotrectinib
Sensitive: A2 - Guideline
ELCC 2023 - 1 week (New C3)
larotrectinib
Sensitive
:
A2
ELCC 2023 - 1wk
larotrectinib
Sensitive: A2 - Guideline
ELCC 2023 - 1 week
larotrectinib
Sensitive
:
A2
ELCC 2023 - 1 week - (New C3)
NTRK1 fusion
Non Small Cell Lung Cancer
NTRK1 fusion
Non Small Cell Lung Cancer
larotrectinib
Sensitive: A2 - Guideline
ELCC 2023 - 1 week (New C3)
larotrectinib
Sensitive
:
A2
ELCC 2023 - 1wk
larotrectinib
Sensitive: A2 - Guideline
ELCC 2023 - 1 week
larotrectinib
Sensitive
:
A2
ELCC 2023 - 1 week - (New C3)
NTRK1 fusion
Lung Non-Small Cell Squamous Cancer
NTRK1 fusion
Lung Non-Small Cell Squamous Cancer
larotrectinib
Resistant: C1 - Off-label
JTO Clin Res Rep - 2 weeks (New C4)
larotrectinib
Resistant
:
C1
JTO Clin Res Rep - 2wk
larotrectinib
Resistant: C1 - Off-label
JTO Clin Res Rep - 2 weeks
larotrectinib
Resistant
:
C1
JTO Clin Res Rep - 2 weeks - (New C4)
NTRK3 fusion
Sarcoma
NTRK3 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK2 fusion
Sarcoma
NTRK2 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK1 fusion
Sarcoma
NTRK1 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK3 fusion
Solid Tumor
NTRK3 fusion
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK2 fusion
Solid Tumor
NTRK2 fusion
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK1 fusion
Solid Tumor
NTRK1 fusion
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
No biomarker
Solid Tumor
No biomarker
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Pancreatic Adenocarcinoma
NTRK3 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Pancreatic Adenocarcinoma
NTRK2 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Adenocarcinoma
NTRK1 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Peritoneal Cancer
NTRK3 fusion
Peritoneal Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Peritoneal Cancer
NTRK2 fusion
Peritoneal Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Peritoneal Cancer
NTRK1 fusion
Peritoneal Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Fallopian Tube Cancer
NTRK3 fusion
Fallopian Tube Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Fallopian Tube Cancer
NTRK2 fusion
Fallopian Tube Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Fallopian Tube Cancer
NTRK1 fusion
Fallopian Tube Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Endometrial Cancer
NTRK2 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Endometrial Cancer
NTRK3 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
NTRK1 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Gastrointestinal Stromal Tumor
NTRK3 fusion
Gastrointestinal Stromal Tumor
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
NTRK1 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Small Intestinal Carcinoma
NTRK2 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Small Intestinal Carcinoma
NTRK3 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Pancreatic Cancer
NTRK3 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Pancreatic Cancer
NTRK2 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Cancer
NTRK1 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Gastrointestinal Stromal Tumor
NTRK2 fusion
Gastrointestinal Stromal Tumor
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Gastrointestinal Stromal Tumor
NTRK1 fusion
Gastrointestinal Stromal Tumor
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login